Indian hospital IPOs are back in focus as Paras Health’s ₹1,450 crore issue opened for subscription on 21 October 2026 and runs to 23 October, with a price band of ₹660 to ₹693 per share. The offer combines a ₹500 crore fresh issue with a ₹950 crore offer for sale by existing shareholders. This industry report looks at the issue structure, the debt-repayment plan, the anchor round, the hospital business and the open questions for readers following the sector. It is not investment advice and does not use unofficial grey-market indicators.
Indian hospital IPOs: key takeaways
- Paras Health’s issue is ₹1,450 crore, reported to be down from ₹1,800 crore originally planned.
- About 66% of the issue is an offer for sale (our arithmetic), so most proceeds go to selling shareholders: promoter Dharminder Kumar Nagar and Commelina.
- Fresh proceeds are reported to fund ₹320.90 crore of company debt repayment and ₹54.10 crore for a subsidiary’s borrowings, a total of ₹375 crore.
- A ₹652.5 crore anchor round from 39 funds was reported at ₹693 per share.
- Listing on BSE and NSE is tentatively set for 28 October.
The issue structure in Indian hospital IPOs
Per published summaries of the offer documents, bidding runs from 21 to 23 October with lots of 21 shares, so one lot is ₹14,553 at the upper band by our arithmetic. Allotment is tentatively 26 October. The book-running lead managers are JM Financial, BofA Securities India and Nuvama Wealth Management, and the registrar is MUFG Intime India. Filings are posted on the NSE offer-documents page, and the Securities and Exchange Board of India and BSE sites carry updates.
The debt-repayment plan in Indian hospital IPOs
According to summaries of the red herring prospectus, ₹320.90 crore of the fresh issue will repay or prepay certain borrowings of the company and ₹54.10 crore will support repayment of borrowings at a wholly owned subsidiary, ₹375 crore in all, with the balance for general corporate purposes. Reported total borrowing was ₹1,393.86 crore at March 2026 against a net worth of ₹394.94 crore, so the repayment is meaningful relative to the balance sheet, though it covers only part of the debt.
Who is selling in Indian hospital IPOs
The offer for sale is reported at up to ₹300 crore by Dharminder Kumar Nagar, a promoter, and up to ₹650 crore by Commelina. This section is our analysis. A large offer for sale is common when a financial investor seeks to realise part of its holding, but it means that the company itself receives only the ₹500 crore fresh issue. The reports we reviewed do not say what stake each seller will hold after the offer, and we do not assume it.
The anchor round among Indian hospital IPOs
Reports published on 21 October say the company raised ₹652.5 crore from 39 anchor investors at ₹693 per share and name SBI Mutual Fund, HDFC Mutual Fund, ICICI Prudential Mutual Fund, Kotak Mutual Fund, Abu Dhabi Investment Authority and BlackRock among them. By our arithmetic that is about 45% of the total issue. Anchor investors commit before the public bidding opens, and their participation signals institutional interest but does not predict subscription or listing outcomes.
The hospital business behind Indian hospital IPOs
The company says it was founded in 1987, is based in Gurugram and operates eight hospitals with 2,211 beds in North India, Bihar and Jharkhand, under the Paras Health brand, with a 300-bed hospital planned in Gurugram and a 500-bed facility in Ludhiana. Restated consolidated total income is reported at ₹1,314.21 crore in FY25 and ₹1,628.78 crore in FY26, with a loss of ₹57.98 crore in FY25 and a profit of ₹43.83 crore in FY26, per the summaries. The company describes itself on its company’s website.
What this means for readers following Indian hospital IPOs
This section is our analysis. Hospital companies need heavy capital for buildings and equipment, and many carry debt, so the use of IPO money to reduce borrowings is a recurring theme. Profitability can swing as new hospitals ramp up. We did not compile a comparison with other listed hospital companies or earlier hospital issues, and we make no claim about how this offer compares. The summaries put the market capitalisation at the offer price at about ₹7,498 crore after the issue, and we offer no view on valuation.
What the reports on Indian hospital IPOs leave out
- Post-offer shareholding of each selling shareholder.
- Final subscription numbers, which change through the bidding window.
- The prospectus text itself, which we did not read; figures are from summaries.
- Sector comparisons and valuation benchmarks.
Risks and caveats on Indian hospital IPOs
- Most of the issue is an offer for sale, and the company reported a loss in FY25.
- Borrowings are high relative to net worth, and expansion depends on new hospitals ramping up.
- Figures here come from summaries of the offer documents and should be checked against the filings.
- Hospital businesses depend on doctor availability, regulation and payer mix, which we have not assessed.
- This is news reporting, not investment advice.
In our assessment, the Paras Health issue is an example of how Indian hospital IPOs often work, with a large selling-shareholder component and fresh money aimed mostly at debt, and readers should rely on the prospectus and exchange data and not on unofficial indicators. See also Sahajanand Medical Technologies IPO: ₹327–₹344 Price Band Announced for ₹475 Crore Issue. More in our industry insights coverage.
What to watch next on Indian hospital IPOs
- Final subscription figures after 23 October.
- Allotment and listing on 26 and 28 October.
- The first results after listing and progress on new hospitals.
Frequently asked questions
How much is the Paras Health issue?
₹1,450 crore, made up of a ₹500 crore fresh issue and a ₹950 crore offer for sale.
How will the fresh money be used?
Mainly to repay borrowings, reported at ₹320.90 crore for the company and ₹54.10 crore for a subsidiary, with the balance for general corporate purposes.
When will the shares list?
Tentatively on 28 October 2026 on BSE and NSE.
How we reported this: we relied on published summaries of the offer documents and anchor-round reports of 21 October 2026, and we point readers to the exchange and regulator pages for the filings. Our analysis is labelled. Last updated: 21 October 2026. This article is news reporting and not investment advice.
